GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types
Philipp Sievers, Damian Stichel, Martin Sill, Daniel Schrimpf, Dominik Sturm, Florian Selt, Jonas Ecker, Daniel Kazdal, Evelina Miele, Mariëtte E.G. Kranendonk, Bastiaan B.J. Tops, Patricia Kohlhof‐Meinecke, Rudi Beschorner, Christof M. Kramm, Martin Hasselblatt, Guido Reifenberger, David Capper, Pieter Wesseling, Albrecht Stenzinger, Till Milde, Andrey Korshunov, Olaf Witt, Stefan M. Pfister, Wolfgang Wick, Andreas von Deimling, David Jones, Felix Sahm
Abstract
Gliomas are the most common primary tumors of the central nervous system (CNS). Among low-grade gliomas, mitogenactivated protein kinase (MAPK) pathway alterations are frequent and may provide a therapeutic target. Currently, mechanism-of-action based therapeutic approaches outside the MAPK pathway are scarce. However, especially patients with subtotally resected, recurrent or highly malignant tumors may substantially benefit from the identification of